Cargando…
How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study
BACKGROUND: In Korea, infliximab was approved for use in children with ulcerative colitis (UC) in October 2012. AIM: To compare the clinical course of UC before and after the introduction of biological agents, and to compare with the IBSEN study. METHODS: Patients under 18 years of age, who were dia...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Baishideng Publishing Group Inc
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372802/ https://www.ncbi.nlm.nih.gov/pubmed/36161040 http://dx.doi.org/10.3748/wjg.v28.i28.3666 |